EOSE
Eos Energy Enterprises, Inc.
There isn't enough reported data to score EOSE yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
EOSE Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
EOSE's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
EOSE PE Valuation
EOSE has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
EOSE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect EOSE's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
EOSE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2023 | -$2.69 | +$0.85 |
| Q2 2023 | -$3.76 | -$1.00 |
| Q1 2023 | -$3.65 | -$0.86 |
| Q4 2022 | -$3.68 | -$1.32 |
| Q3 2022 | -$3.54 | +$5.19 |
OSCR has the stronger earnings trend. Trailing diluted EPS is down 224% for EOSE versus OSCR up 147%.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
EOSE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $82.7M | +171% |
| Q2 2026 | $68.8M | +351% |
| Q1 2026 | $57M | +445% |
| Q4 2025 | $58M | +700% |
| Q3 2025 | $30.5M | +3473% |
| Q2 2025 | $15.2M | +1597% |
| Q1 2025 | $10.5M | +58% |
| Q4 2024 | $7.3M | +9.7% |
EOSE has the edge over OSCR on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -96% | +105 points |
| Q2 2026 | -122% | +297 points |
| Q1 2026 | -139% | +367 points |
| Q4 2025 | -140% | +573 points |
| Q3 2025 | -201% | +6044 points |
| Q2 2025 | -419% | +2815 points |
| Q1 2025 | -506% | +117 points |
| Q4 2024 | -713% | -74 points |
EOSE's operating margin was −96% last quarter, up 105 points from the same quarter a year ago, near the top of its range since 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over EOSE on profitability, with a higher operating margin.
EOSE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$105.1M | -$22.4M |
| Q2 2026 | -$107.4M | -$34.3M |
| Q1 2026 | -$154.8M | -$121M |
| Q4 2025 | -$75.2M | -$19.5M |
| Q3 2025 | -$82.7M | -$28.5M |
| Q2 2025 | -$73.2M | -$40.6M |
| Q1 2025 | -$33.8M | +$10.7M |
| Q4 2024 | -$55.8M | -$10.2M |
EOSE has burned cash in almost every quarter: −$443M over the past year, against −$246M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over EOSE on cash generation, producing positive trailing cash flow while its opponent burns cash.
EOSE Net Leverage
EOSE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
EOSE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.5 | Neutral |
| Stochastic | 7.4 | Oversold |
EOSE's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
EOSE PE vs Industrials Sector
EOSE has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
EOSE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.24 | 19% below |
| 20 week MA | $3.28 | 45% below |
| 50 week MA | $7.01 | 74% below |
| 100 week MA | $7.10 | 75% below |
| 200 week MA | $4.53 | 60% below |
EOSE is in a downtrend: it's below all five of its weekly moving averages, and 60% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over EOSE on trend strength, trading above more of its moving averages.
EOSE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.72 | $19.2 | +98% |
| 2021 | $19.2 | $8.57 | -55% |
| 2022 | $8.57 | $1.08 | -87% |
| 2023 | $1.08 | $1.09 | +0.9% |
| 2024 | $1.09 | $5.17 | +374% |
| 2025 | $5.17 | $11.9 | +129% |
| 2026 YTD | $11.9 | $1.81 | -85% |
EOSE's yearly returns have swung widely, from +374% in 2024 to −87% in 2022. It's down 85% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over EOSE on returns for 2026, with the stronger performance.